x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

18:42

190. Back to Basics - Mesothelioma

Oncology for the Inquisitive Mind ·

2026/02/21

Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment options for pleural mesothelioma, including ipilimumab and nivolumab, and consider whether chemotherapy and bevacizumab work for mesothelioma as well. The MAPS trial was published in 2016, while Checkmate was published in 2022.Studies discussed in this episode:MAPSCheckmate 743For

en

21:18

189. Back to Basics - Extensive Stage Small Cell Lung...

Oncology for the Inquisitive Mind ·

2026/02/16

This week, we return to our regular programming with a back-to-basics exploration of extensive small-cell lung cancer. A notorious killer and an aggressive type of lung cancer, it has seen new treatments developed at a faster rate than in the last twenty years combined.We explore tarlatamab, a bispecific delta-like ligand 3-directed T cell engager. The results show that, in the second-line setting, it improves overall survival (spoiler alert). The second study is IMforte, utilising lurbinectedin

en

35:25

188. Gastrointestinal Cancer and Professor Jenny...

Oncology for the Inquisitive Mind ·

2026/02/11

Today, our guest is a transformative figure in bowel cancer treatment. Professor Jenny Seligmann, a Consultant Medical Oncologist and Professor of Gastrointestinal and Translational Oncology at the University of Leeds, is renowned for leading the groundbreaking FOxTROT and ARIEL trials. These studies challenged traditional practices by demonstrating the advantages of administering chemotherapybeforesurgery, a change now saving lives and influencing worldwide protocols. As a devoted mentor and a

en

39:10

187. ESMO Awards - Episode 7

Oncology for the Inquisitive Mind ·

2026/02/02

In our final take on ESMO 2025, we talk about Genitourinary Cancers. This was a dense area with numerous trials. Today we explore distimiab vedotin in those with advanced bladder cancer, the role of combining lutetium with an ARPI in advanced prostate cancer, whether de-escalation of docetaxel in high volume prostate cancer was just as efficacious as the regular six cycles, immunotherpay plus bCG in non-muscle invasive bladder cancer, adjuvant durvalumab in renal cell caricnoma and the perioperaive

en

21:53

186. ESMO Awards - Episode 6

Oncology for the Inquisitive Mind ·

2026/01/25

ESMO Episode 6 is here! The longest award ceremony in the world continues. This episode covers colorectal cancer, a cancer stream that has relied heavily on the same three drugs for the past twenty-five years.We cover the golden pinnacle of real-world use cases for CTDNA, neoadjuvant immunotherapy in those with proficient MMR colorectal cancer, whether Zanzalimab helps in refractory colorectal cancer, and much more.Studies:BREAKWATERNEOADJUVANT IMMUNOTHERAPY (pMMR)STELLAR-303CHECKMATE 8HWFor more

en

31:34

185. ESMO Awards - Episode 5

Oncology for the Inquisitive Mind ·

2026/01/21

We're back, baby! Michael and Josh predicted their ESMO journey would have eons to run, and they weren't wrong! For our first episode back in 2026, we revisit the important coverage of ESMO 2025, highlighting advances in upper gastrointestinal tract and hepatobiliary cancers. This episode covers FGFR inhibitors (Bemartizumab), updates on the MATTERHORN trial, the use of immunotherapy with trastuzumab and FLOT in HER2-positive localised oesophageal carcinoma, and investigates the use of TKIs and the

en

33:48

184. ESMO Awards - Episode 4

Oncology for the Inquisitive Mind ·

2025/12/13

This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies.Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex

en

28:33

183. ESMO Awards - Episode 3

Oncology for the Inquisitive Mind ·

2025/12/05

For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer.Studies:DeLLphi-303SOHO-01ALBATROSPAULIENDREAM3ROptiTROP-Lung04For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats:

en

42:16

182. ESMO Awards - Episode 2

Oncology for the Inquisitive Mind ·

2025/11/26

ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world.Studies:SOLTI-RIBOLARISPOSITIVEmonarchE:DESTINY-Breast11evERAASCENT-03TROPION-Breast02 trialROSELLADICE trialENGOT-ov65/KEYNOTE-B96 studyROSELLAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial

en

34:06

182. ESMO Awards, Episode 1

Oncology for the Inquisitive Mind ·

2025/11/15

After a short break for some pretty major life changes (more details in the episode), Josh and Michael return to tackle the best and brightest of ESMO 2025. With support from MSD, our dynamic duo play host to the inaugural Oncology for the Inquisitive Mind Awards. Today, they look at studies in pre-clinical science, supportive care and rare cancers to find their favourite studies amidst the goldmine that was this year's European Oncology Extravaganza.For more episodes, resources and blog posts,

en

22:20

181. Back to Basics - Limited Stage Small Cell Lung...

Oncology for the Inquisitive Mind ·

2025/10/18

In this episode, the focus shifts away from the more "garden-variety" non-small cell lung cancer and to its less common, frequently more aggressive sibling, small cell lung cancer. Here, Josh and Michael examine the management of limited-stage small cell lung cancer, which while accounting for a minority of cases, is no less interesting and potentially confusing. Studies discussed in this episode:PCI Meta AnalysisADRIATICFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease

en

18:12

180. Metastatic NSCLC feat. KRAS and MET mutations

Oncology for the Inquisitive Mind ·

2025/10/12

On this week's episode, Josh and Michael exchange the established treatment landscape of EGFR and ALK mutant NSCLC for the developing management of disease harbouring KRAS and MET mutations. The most common mutation meets one of the least common in this battle of therapeutic tenacity.Studies discussed in this episode:INSIGHT-2KRYSTAL-12For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or

en

24:44

179. Back to Basics: Metastatic NSCLC feat. EGFR and...

Oncology for the Inquisitive Mind ·

2025/10/05

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? You'll just have to listen and find out.Studies discussed in this episode:MARIPOSACROWNFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look

en

19:22

178. Back to Basics - Metastatic Non Small Cell Lung...

Oncology for the Inquisitive Mind ·

2025/09/27

Advanced or Metastatic Non Small Cell Lung Cancer (mNSCLCa), is one of the most common causes of death worldwide. This week, Michael provides an excellent background on this type of cancer, and Josh provides an eloquently short introduction (for once). These trials look specifically at lung cancers without mutations, thus relying on immunotherapy and chemotherapy.As a side note, can you believe Keynote189 is over 7 years old! How time flies!Studies discussed in this episode:Keynote 189Checkmate

en

24:01

177. Early NSCLC

Oncology for the Inquisitive Mind ·

2025/09/13

To Josh's immense displeasure, our series on genitourinary cancer is done. For now, at least. In this episode, Michael and Josh step into the heavy shadow of non-small cell lung cancer, the most common cause of cancer death in Australia. However, there is hope and new developments in the early-disease space that could significantly improve outcomes. Studies discussed in this episodeCheckmate 816neoADAURAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on

en

18:32

176. Germ cell tumours (part 2)

Oncology for the Inquisitive Mind ·

2025/09/06

In this episode, Michael and Josh continue to unpick the thorny question of germ-cell tumours, focusing this week on more advanced and relapsed disease. Germ cell tumours have an excellent prognosis, but unfortunately there are cases where more intense therapy is required. Listen on to find out about what to do when first line therapy is not enough!Studies discussed in this episodeBEP - Williams et al (1987)TIP - Gleeson et al (20224)For more episodes, resources and blog posts, visit

en

18:34

175. Germ Cell Tumours (part 1)

Oncology for the Inquisitive Mind ·

2025/08/30

This episode is the first of a two-part mini-series where Michael and Josh attempt to untangle the complex topic of germ cell tumours, an area that requires specialist experience and a high-volume multi-disciplinary centre to treat adequately. Or, you could just listen to Oncology for the Inquisitive Mind and be a pro in no time!Studies discussed in this episodeEORTC-30982de Wit et al (2001)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter

en

20:05

174. Non clear-cell RCC

Oncology for the Inquisitive Mind ·

2025/08/24

In this episode, Josh and Michael take a trip down a road less travelled by both patients and researchers, and examine the evidence (or lack thereof) of non-clear cell renal cell cancer, a less common cluster of siblings to the much better established clear cell RCC. Treatment is on very similar patterns, so their studies today involve a lot of immunotherapy with a smattering of tyrosine kinase inhibitors.Studies discussed in this episodeKEYNOTE-B61Checkmate 920For more episodes, resources and blog

en

19:08

173. NECTA (New South Wales Early Phase Clinical...

Oncology for the Inquisitive Mind ·

2025/08/17

How do you increase access to phase 1 trials for a state with a population of 8 million people spread across 800,000 km^2? You collaborate! In this context, we explore NECTA. The New South Wales Early Phase Clinical Trials Alliance (NECTA) plays a key role in speeding up the translation of cutting-edge medical research into real-world treatments, providing vital benefits to patients and the broader healthcare system. By uniting a network of leading hospitals, research institutions, and clinical

en

19:25

172. Back to Basics - Advanced ccRCC

Oncology for the Inquisitive Mind ·

2025/08/09

Unlike the adjuvant space, treatment of advanced clear cell renal cell cancer has been a success story potentially only surpassed by advanced melanoma. What was once a horrific and quickly fatal disease, with a predilection for the CNS and significant bleeding risk has become significantly less so. In this episode, Josh and Michael explore the studies that have made it happen.Studies discussed in this episodeCLEARCheckmate 214Checkmate 9ERFor more episodes, resources and blog posts, visit

en

208 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown